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Abstract
To prevent excessive inflammatory responses to commensal microbes, intestinal macrophages
unlike their systemic counterparts do not produce inflammatory cytokines in response to enteric
bacteria. Consequently, loss of macrophage tolerance to the enteric microbiota plays a central role
in the pathogenesis of the inflammatory bowel diseases. Therefore, we examined whether the
hyporesponsive phenotype of intestinal macrophages is programmed by prior exposure to the
microbiota. IL-10, but not in vivo exposure to the microbiota, programs intestinal macrophage
tolerance, as wild-type (WT) colonic macrophages from germ free and specific-pathogen free
(SPF) derived mice produce IL-10 but not IL-12 p40 when activated with enteric bacteria. Basal
and activated IL-10 expression is mediated through a MyD88 dependent pathway. Conversely,
colonic macrophages from germ free and SPF derived colitis-prone Il10−/− mice demonstrated
robust production of IL-12 p40. Next, mechanisms through which IL-10 inhibits Il12b expression
were investigated. While Il12b mRNA was transiently induced in LPS-activated WT bone marrow
derived macrophages (BMDMs), expression persisted in Il10−/− BMDMs. There were no
differences in nucleosome remodeling, mRNA stability, NF-κB activation or MAPK signaling to
explain prolonged transcription of Il12b in Il10−/− BMDMs. However, acetylated histone H4
(AcH4) transiently associated with the Il12b promoter in WT BMDMs, whereas association of
these factors was prolonged in Il10−/− BMDMs. Experiments utilizing histone deacetylase
(HDAC) inhibitors and HDAC3 shRNA indicate that HDAC3 is involved in histone deacetylation
of the Il12b promoter by IL-10. These results suggest that histone deacetylation on the Il12b
promoter by HDAC3 mediates homeostatic effects of IL-10 in macrophages.
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The gastrointestinal tract represents a complex interface between the enteric microbiota and
immune cell populations. A multitude of diverse microorganisms reside in the intestinal
lumen separated from the body’s largest reservoir of macrophages by a single layer of
epithelial cells. These macrophages serve as the first line of defense against the external
environment. To prevent excessive inflammatory responses to commensal microbes,
intestinal macrophages have acquired a unique phenotype. Intestinal macrophages, unlike
their systemic counterparts, do not produce inflammatory cytokines in response to enteric
bacteria (1). Consequently, loss of macrophage tolerance to the enteric microbiota plays a
central role in the pathogenesis of the inflammatory bowel diseases (IBD) (2, 3).
The anti-inflammatory cytokine IL-10 is implicated in the maintenance of intestinal
homeostasis. Mutations in genes encoding the IL-10 receptor subunit proteins IL10RA and
IL10RB were reported in patients with early onset enterocolitis (4). Moreover, mice
deficient in IL-10 or IL-10 receptors develop spontaneously occurring intestinal
inflammation dependent on the presence of the enteric microbiota (5, 6). IL-10 is secreted
by many cell types, including T cells, mast cells, epithelial cells, macrophages, and dendritic
cells; however, a major source of IL-10 involved in the maintenance of intestinal
homeostasis is lamina propria or mesenteric lymph node macrophages (7–9).
The IL-12 family members IL-12 and IL-23 expressed by macrophages are important
inhibitory targets of IL-10 and are central mediators of chronic intestinal inflammation (10–
13). IL-12/IL-23 p40 (encoded by the Il12b gene) is the common subunit of IL-12 and
IL-23. Despite extensive investigation, molecular mechanisms through which IL-10 inhibits
Il12b expression have not been fully elucidated (14–16).
Gene transcription is regulated at the chromatin level. DNA-binding factors cannot access
DNA in closed chromatin. Therefore, chromatin structure needs to be altered to facilitate
gene transcription (17). Histone acetylation induces an open chromatin conformation that
allows the transcription machinery to access promoters, whereas histone deacetylation
correlates with gene silencing. Inducible chromatin modifications serve as important
restriction points in TLR-regulated gene expression. Recruitment of histone
acetyltransferases (HATs) such as p300 and CREB-binding protein (CBP) to the Il12b
promoter has been implicated in its transcriptional activation (18). TLR stimulation of
macrophages results in rapid changes in chromatin remodeling at the Il12b locus via histone
acetylation, enabling transcription factor recruitment (17). Accordingly, histone
deacetylation on the Il12b promoter by histone deacetylase (HDAC) negatively regulates
Il12b transcription (19). Therefore, epigenetic changes that inhibit and induce Il12b
expression in macrophages are likely to be central determinants of intestinal homeostasis
and inflammation, respectively.
Here, we report that the anti-inflammatory phenotype of resident colonic macrophages is
programmed by IL-10 without requirement for exposure to the microbiota in vivo. In bone
marrow derived macrophages (BMDM), IL-10 inhibits IL-12/IL-23 p40 expression through
altered kinetics of histone acetylation on the Il12b promoter. Inhibition of HDAC3 results in
decreased inhibition of Il12b by IL-10. These experiments suggest that histone deacetylation
on the Il12b promoter by HDACs mediates homeostatic effects of IL-10 in macrophages.
Consequently, the absence of IL-10 leads to prolonged histone acetylation with persistent
transcription of Il12b.
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Wild-type (WT) and Il10−/− mice on 129/SvEv background were used to isolate colonic
CD11b+ lamina propria mononuclear cells (LPMCs). IL-10–IRES-EGFP reporter (Vert-X)
mice were created by insertion of a floxed neomycin–IRES-EGFP cassette between the
endogenous stop site and the polyadenosine site of IL-10 (20). Germ-free (GF) mice were
maintained in the Gnotobiotic Core Facility at the University of North Carolina at Chapel
Hill. WT and Il10−/− mice on C57BL/6 background maintained in specific-pathogen free
(SPF) condition were used for bone marrow derived macrophage (BMDM) derivation. All
animal experiments were in accordance with protocols approved by the International Animal
Care and Use Committee of the University of North Carolina at Chapel Hill.
Reagents
LPS was purchased from InvivoGen (San Diego, CA). M-CSF and IL-10 were obtained
from PeproTech Inc (Rocky Hill, NJ). Heat-killed bacteria was prepared as described
previously (1). Briefly, E. coli and E. faecalis in log-phase growth were harvested and
washed twice with ice-cold PBS. Bacterial suspensions were heated at 80°C for 30 minutes,
washed, resuspended in PBS, and stored at −80°C. Non-viability was confirmed by 72-hour
incubation at 37°C on plate medium. Heat-killed bacteria were added at multiplicity of
infection (MOI) 10 or 100 for cell stimulation. HDAC inhibitors, trichostatin A (TSA) and
MS275 were obtained from Sigma (St. Louis, Mo) and Selleck Chemicals (Houston, TX),
respectively.
Cell isolation
BMDMs were cultured as described previously (21). LPMCs were isolated from mouse
colons by an enzymatic method as previously described (1). LPMCs were further separated
into CD11b+ cells using anti-CD11b microbeads (Miltenyi Biotec, Auburn, CA).
Quantitative RT-PCR
Quantitative real-time RT-PCR was performed as described previously (22). Primer
sequences are available upon request.
Chromatin immunoprecipitation assays (ChIP)
ChIP was performed with ChIP-IT Express kit (Active Motif, Carlsbad, CA) according to
manufacturer’s instruction and as previously reported (23, 24). Briefly, 2×106 (for AcH4,
me3H3K4) or 5×106 (for RNA polymerase II (RNA Pol II)) BMDMs were stimulated,
washed with PBS, and fixed with 1% formaldehyde for 10 minutes at room temperature.
Fixed cells were harvested, lysed, and sonicated for 10 cycles of 20-second on/20-second off
with Sonic Dismembrator 60 (Thermo Fisher Scientific, Waltham, MA). For AcH4 ChIP,
sodium butyrate (20 mM) was added to all the solutions to preserve histone acetylation.
Antibodies for AcH4 and RNA pol II were obtained from Millipore (Billerica, MA), and
me3H3K4 was from Abcam (Cambridge, MA). Primer pairs for monitoring binding to Il12b
promoter were as follows: acetylated histone H4 (AcH4), forward 5′-
ATGCACTCAGGGAGGCAAG-3′, reverse 5′-
TCTGATGGAAACCCAAAGTAGAAAC-3′, RNA polymerase II (RNA Pol II), Forward
5′-GAAGGAACAGTGGGTGTCCAG-3′, Reverse 5′-
AGGGAGTTAGCGACAGGGAAG-3′.
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Restriction enzyme accessibility assay
To monitor nucleosome remodeling, chromatin accessibility was measured by real-time
PCR as previously described (25, 26). Purified DNA was amplified by three sets of primers.
PCR-based analysis was validated by Southern blot, as described (25) (Supplemental Fig. 1).
Lentivirus-mediated gene transduction
Lentiviral transduction was optimized based on manufacturer’s instructions for FuGENE
Transfection Reagent (Roche, Indianapolis, IN) and as previously described (23). Lentivirus
for HDAC3-specific shRNA was obtained from Open Biosystems (Huntsville, AL) and
transduced to BMDMs from Il10−/− mice in 12-well plates. Transduced cells were selected
by puromycin, and transduction efficiency was confirmed by Western blot and RT-PCR.
Enzyme-linked immunosorbent assay (ELISA)
IL-12 p40 and IL-10 concentrations were determined by sandwich ELISA according to the
manufacturer’s instructions (BD Biosciences, San Jose, CA).
Western immunoblots
Western blot analyses were performed on whole cell extracts as described previously (21).
NF-κB p65, IκBα, phospho-p38, and phospho-ERK antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA), phospho-NF-κB p65, phospho-IκBα, and phospho-
JNK antibodies were obtained from Cell Signaling (Danvers, MA).
Statistical analysis
Statistical significance for data subsets were assessed by the two-tailed Student’s t test. p
values < 0.05 were considered to be significant. All data are expressed as mean ± standard
error (SEM).
RESULTS
IL-10 but not the enteric microbiota programs the anti-inflammatory phenotype of colonic
macrophages
Germ free (GF) Il10−/− mice, but not wild type (WT) mice, develop colitis when colonized
with the enteric microbiota (27). Colitis in Il10−/− mice is associated with increased colonic
production of IL-12/23 p40 (24). As peripheral macrophages become tolerized to activation
of inflammatory pathways upon prolonged or repeated exposure to pathogen associated
molecular patterns (28, 29), we reasoned that colonic macrophages may require exposure to
the enteric microbiota in vivo to develop a tolerant, anti-inflammatory phenotype. To
address this question, colonic CD11b+ lamina propria mononuclear cells (LPMCs) were
isolated from GF and specific pathogen free (SPF) colonized WT mice (Fig. 1A and B).
Surprisingly, CD11b+ LPMCs from GF WT mice activated with heat killed E. coli or E.
faecalis did not express IL-12/23 p40 (Fig. 1A), but secrete basal and activated IL-10 (Fig.
1B). This suggests that the anti-inflammatory phenotype is programmed by factors in the
local microenvironment and does not require in vivo exposure to the enteric microbiota.
CD11b+ LPMCs isolated from SPF colonized WT mice demonstrated patterns of IL-12/23
p40 and IL-10 expression identical to that of CD11b+ LPMCs from GF WT mice (Fig. 1A
and B). Interestingly, CD11b+ LPMCs from GF Il10−/− mice demonstrate IL-12/23 p40
production upon activation with E. coli and E. faecalis (Fig. 1A). Indeed, IL-12 p40
activation was as robust in GF CD11b+ LPMCs as in CD11b+ LPMCs from SPF colonized
Il10−/− mice (Fig. 1A). No difference was observed in expression of surface markers (F4/80,
CD11c, CD40, MHC II, CD80, CD86) between WT and Il10−/− CD11b+ LPMCs (from GF
or SPF colons). CD40, CD86 and MHC II expression appeared to be higher in GF compared
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to SPF CD11b+ LPMCs, although these differences did not impact Il10 or Il12b expression
(Supplemental Fig. 2). To substantiate the role of IL-10 in determining colonic macrophage
phenotype, CD11b+ LPMCs from GF WT colons were cultured with blocking antibodies to
IL-10 and IL-10 receptor prior to activation with heat-killed E. coli and E. faecalis. By
blocking IL-10 signaling, activated WT colonic CD11b+ LPMCs demonstrate robust
production of IL-12/23 p40 compared to CD11b+ LPMCs cultured with isotype control
antibodies (Fig. 1C). These results indicate that endogenous IL-10 production is essential for
the regulation of IL-12 p40 and consequently, the anti-inflammatory phenotype of colonic
macrophages. Interestingly, IL-10 production by colonic CD11b+ LPMCs was MyD88-
dependent (Fig. 1D): Both basal and enteric bacteria-activated IL-10 expression is absent in
colonic CD11b+ LPMC from SPF colonized Myd88−/− but not Trif−/− mice, suggesting that
endogenous signals through MyD88 control homeostatic macrophage function. The in vivo
expression of IL-10 in different subsets of CD11b+ cells was further elucidated using IL-10
transcriptional GFP reporter mice, Vert-X mice (20). First, IL-10 expressing cells were
quantitated and compared in colonic CD11b+CD11c− macrophage and CD11b+ CD11c+
dendritic cell populations from SPF-raised Vert-X mice. CD11b+CD11c− macrophages
demonstrated greater numbers of IL-10 producing cells compared to CD11b+CD11c+
dendritic cells, as reported previously (30) (Fig. 1E). We confirmed that the presence and
abundance of IL-10 producing CD11b+CD11c− macrophages was independent of
colonization status by the enteric microbiota in Vert-X mice raised in GF, SPF or transferred
from GF to SPF microbiota (Fig. 1F). Overall, these findings implicate locally produced
IL-10, not exposure to the microbiota, as a requisite factor determining colonic macrophage
phenotype through attenuated expression of IL-12/23 p40 upon subsequent exposure to
enteric microbial products.
IL-10 regulates Il12b in macrophages through epigenetic mechanisms
M-CSF-derived bone marrow derived macrophages (BMDMs) produce more IL-10 and less
IL-12 p40 compared to GM-CSF-derived BMDM (1). Therefore, we utilized M-CSF-
derived BMDMs as a model to explore molecular mechanisms through which IL-10
attenuates Il12b activation. Indeed, kinetics of Il12b and Il10 expression was similar
between LPS-stimulated BMDMs and heat-killed bacteria-stimulated colonic macrophages
from WT and Il10−/− mice (Fig. 2A, B). LPS-induced Il12b mRNA was transient in WT
BMDMs with peak expression at 3 hours. However, Il12b expression from Il10−/− BMDMs
was still increasing at 12 hours (Fig. 2A). In the presence of anti-IL-10, the kinetics of Il12b
expression in WT BMDMs was identical to Il10−/− BMDMs (Fig. 2C). There was no
detectable difference in Il12b mRNA stability between WT and Il10−/− BMDMs (Fig. 2D).
NF-κB (IκBα phosphorylation and degradation, RelA phosphorylation) and MAPK kinase
activation kinetics were also identical in WT and Il10−/− BMDMs (Fig. 2E), with peak
activation between 0.5 and 3 hours. Interestingly, when exogenous IL-10 was added to
Il10−/− BMDMs 3 hours post-LPS stimulation, Il12b expression was still attenuated at later
time points (Fig. 2F). These results suggest that IL-10 inhibits IL-12 p40 not through altered
induction of downstream signal transduction pathways, but through other mechanisms that
affect gene transcription.
IL-10 alters histone H4 acetylation kinetics on the Il12b proximal promoter
Gene expression is regulated at the chromatin level through nucleosome remodeling and
covalent histone modifications. Histone acetylation is associated with transcriptionally
active chromatin, whereas deacetylation correlates with gene repression. Upon LPS
stimulation, Il12b promoter activation is accompanied by selective remodeling of a
nucleosome (referred to as Nuc1) in the proximal promoter and a DNase I hypersensitive
site (HSS1) approximately 10 kb upstream of the transcription start site (16). As previously
described (25), restriction enzyme accessibility assays revealed that Nuc1 and HSS1 were
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remodeled upon LPS stimulation of WT BMDMs (Fig. 3A and B; Confirmation by Southern
blot shown in Supplemental Fig. 1). Il10−/− BMDMs demonstrated identical kinetics of
nucleosome remodeling, despite the marked difference in Il12b expression kinetics between
WT and Il10−/− BMDMs. Therefore, we next examined histone modifications on the Il12b
promoter by chromatin immunoprecipitation (ChIP) using acetylated histone H4 as an
indicator of open chromatin. Histone H4 on the Il12b promoter was transiently acetylated in
WT BMDMs, peaking at 1.5 hours after LPS stimulation and decreasing to baseline by 3
hours, whereas histone H4 acetylation on the Il12b promoter persisted for 6 hours in Il10−/−
BMDMs (Fig. 3C). Recombinant IL-10 inhibited LPS-induced histone acetylation on the
Il12b promoter in Il10−/− BMDMs (Fig. 3D). In contrast, trimethylation of histone H3 at
lysine 4 (H3K4me3), another marker of transcriptionally active promoters, was induced
upon LPS stimulation and persisted at 6 hours in both WT and Il10−/− BMDMs
(Supplemental Fig. 3A), whereas Il12b mRNA is decreasing at 6 hours post-LPS in WT
BMDMs (Fig. 2A). This suggests that IL-10 specifically induces histone deacetylation on
Il12b promoter.
Histone deacetylation decreases the accessibility of chromatin to the basal transcriptional
machinery. Therefore, we next determined whether IL-10-mediated histone deacetylation
correlates with decreased occupancy of RNA polymerase II (RNA pol II) on the Il12b
promoter. LPS-stimulated WT BMDMs demonstrated transient RNA pol II occupancy on
the Il12b promoter. In Il10−/− BMDMs, RNA pol II occupancy persisted for 6 hours
following LPS stimulation (Fig. 3E). Recombinant IL-10 inhibited RNA pol II binding in
Il10−/− BMDMs (Fig. 3F). Kinetics of NF-κB p65 recruitment to the Il12b promoter was
also similar to RNA pol II in WT and Il10−/− BMDMs and binding of p65 was also inhibited
by exogenous IL-10 (Supplemental Fig. 3B and C), similar to findings in bone marrow
derived dendritic cells described previously (31). Taken together, these results demonstrate
that IL-10 limits transcriptional activity of the Il12b promoter, likely through alterations in
histone acetylation kinetics.
Inhibition of LPS-induced IL-12 p40 by IL-10 involves histone deacetylation by HDAC3 in
bone marrow derived and colonic macrophages
The altered kinetics of histone acetylation led us to study the role of HDACs in IL-10-
mediated Il12b inhibition. We first used an inhibitor of class I and II HDACs, trichostatin A
(TSA). Pretreatment of BMDMs with TSA prior to LPS stimulation significantly inhibit
Il12b transcription induction, as previously described (32) (Supplemental Fig. 4A), greatly
affecting our ability to detect IL-10 mediated inhibition of Il12b transcription. Therefore,
Il12b transcription was first induced with LPS for one hour before treating the BMDMs with
TSA. Interestingly, TSA prolonged the expression of Il12b in WT BMDMs resulting in
kinetics similar to that in Il10−/− BMDMs (Fig. 4A). However, TSA also affected the
kinetics of other cytokines, including IL-10 (Supplemental Fig. 4B). Next, exogenous IL-10
was added back to Il10−/− BMDMs in the presence or absence of TSA to compare IL-10-
induced deacetylation on the Il12b promoter without potential confounding effects mediated
by endogenous IL-10 production (Fig. 4B). As predicted, inhibition of IL-12 p40 by IL-10
was significantly impaired by TSA(Fig. 4C). Quantitative PCR also showed marked
decrease of Il12b inhibition by IL-10 in the presence of TSA (Fig. 4C), suggesting IL-10
mediated inhibition of LPS-induced IL-12 p40 is partially dependent on class I or II
HDACs.
Since HDAC1 is reported to be associated with histone deacetylation on the Il12b and Il6
promoters in macrophages (19, 33), we next utilized the HDAC1- and 3- specific inhibitor
MS275 (IC50 0.3 μM for HDAC1 and 8 μM for HDAC3). Unexpectedly, loss of IL-10
mediated inhibition of Il12b was observed only at the highest dose of MS275 (10 μM),
suggesting HDAC3 is more important to this process (Fig. 4D and E). HDAC3-specific
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lentiviral shRNA(Fig. 4F) was used to confirm this role of HDAC3 in the inhibitory effect
of IL-10 on LPS-induced IL-12 p40. IL-12 p40 inhibition by IL-10 was significantly
diminished in LPS and HDAC3 shRNA-treated cells compared to control cells (scrambled
HDAC3 shRNA) (Fig. 4G). Furthermore, inhibition of HDAC3 prevented histone H4
deacetylation on the Il12b promoter by IL-10 (Fig. 4H).
HDAC3 is a homeostatic factor in IL-10-mediated intestinal immunity
To determine whether our findings in BMDMs are relevant for colonic macrophage
function, IL-12 p40 production by colonic CD11b+ LPMCs from Il10−/− mice was
determined in the presence of HDAC inhibitors. Il10−/− colonic CD11b+ LPMCs were
activated with heat killed E.coli prior to the addition of MS275 or TSA and IL-10. As
demonstrated in BMDMs, IL-12 p40 inhibition by IL-10 was significantly diminished by
blocking HDAC3 compared to the control (Fig. 5A). Next, colonic Hdac3 expression was
characterized before and after transition of GF mice to an SPF microbiota (34). Interestingly,
colonic Hdac3 expression was significantly induced after colonization of WT mice, but not
colitis-prone Il10−/− mice (Fig. 5B). Colonic Il12b expression was significantly induced in
Il10−/− but not WT mice upon exposure to SPF microbiota, inversely correlating with Hdac3
induction. As a control, no significant induction of colonic Hdac1 was observed (Fig. 5B).
DISCUSSION
Mechanisms operative in programming an anti-inflammatory phenotype in intestinal
macrophages are incompletely understood. We initially speculated that a tolerant colonic
macrophage phenotype might be acquired upon exposure to the enteric microbiota. Given
this unique intestinal environment where macrophages intimately coexist with the enteric
microbiota, we hypothesized that a phenomenon similar to the induction of endotoxin
tolerance in peripheral macrophages may occur (28, 29). However, colonic macrophages
isolated from GF WT mice were phenotypically identical to macrophages derived from
colonized mice, and failed to produce Il12b upon stimulation with enteric bacteria.
Moreover, both GF and SPF WT colonic macrophages produced abundant IL-10. Colonic
macrophages from GF Il10−/− mice and WT macrophages treated with anti-IL-10/IL-10
receptor antibodies produced abundant IL-12 p40 upon activation by enteric bacteria,
demonstrates that locally produced IL-10 is a requisite factor for maintaining anti-
inflammatory responses in colonic macrophages. It is also intriguing that MyD88-deficient
intestinal macrophages lack both basal and inducible IL-10. Further studies are needed to
unravel precise mechanisms by which intestinal macrophages acquire the anti-inflammatory
phenotype to produce IL-10 through MyD88. Speculatively, endogenous factors that
activate the MyD88 signaling pathway in the colonic microenvironment may shape the
colonic macrophage phenotype and mediate tolerance to the enteric microbiota. However,
given inherent limitations of the germ free mouse model system, we also cannot exclude
exogenous microbial products and other exogenous substance present in small amounts in
the mouse diet as contributing to this process. Nonetheless, these results further define the
unique immune environment in the gastrointestinal tract, focusing on IL-12 p40 regulation
by endogenous IL-10 production as a well established prototype for a mucosal innate
inflammatory response.
Utilizing BMDMs as a model to understand molecular mechanisms through which IL-10
inhibits Il12b expression, IL-10 was found to mediate histone deactelyation of the Il12b
promoter with the consequence of attenuated transcription of Il12b. In Il10−/− BMDMs,
prolonged kinetics of Il12b mRNA and protein expression correlated with prolonged histone
H4 acetylation on the proximal promoter and prolonged occupancy by RNA pol II. Zhou et
al. previously demonstrated that exogenous IL-10 abolishes RNA pol II binding to the Il12b
promoter partly through inhibition of nucleosome remodeling of the Il12b promoter (16).
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While our results also demonstrated altered RNA pol II recruitment, we did not observe
differences in nucleosome remodeling between WT and Il10−/− BMDMs. An important
difference between our studies is that they used peritoneal macrophages. Additionally,
alterations of nucleosome remodeling demonstrated in the prior study were relatively small
in magnitude compared with profound IL-12 p40 inhibition by exogenous addition of
recombinant IL-10. Indeed, the authors speculated that alterations in nucleosome remodeling
induced by IL-10 were likely to be a consequence of transcription inhibition rather than the
cause. Furthermore, comparisons between WT and Il10−/− BMDMs may be more relevant to
dissect molecular differences given that we demonstrate the importance of autocrine
regulation of IL-12 p40 by endogenous IL-10 (Fig. 1C and 2C).
Although our studies clearly implicate HDAC3 in the inhibitory effect of IL-10 on Il12b, it
is important to note that the inhibitory effect was not complete. Indeed, HDAC inhibitors
reverse approximately 30% of the inhibitory effect of IL-10. Based on many other studies
looking at mechanisms of IL-10 inhibition, this is not surprising. IL-10 is such an important
homeostatic factor that multiple independent mechanisms must mediate its inhibitory effect
even on a single gene such as IL-12 p40, because the consequences of loss of IL-10
regulation are so significant biologically. Indeed, IL-10 induces many genes in macrophages
at the same time as it inhibits others (35) and exerts its potent anti-inflammatory function in
innate immunity through multiple mechanisms. Transcription elongation (36), miR-155
(37), and induction of transcriptional repressors such as tristetraprolin (38), ETV3, and
Strawberry notch homologue 2 (SBNO2) (39) have been suggested as mechanisms for
IL-10-mediated innate immune regulation, although they have not been explicitly implicated
in IL-12 p40 inhibition. Accordingly, multiple redundant mechanisms for IL-10-mediated
IL-12 p40 regulation have been described, including nuclear factor, interleukin-3 regulated
(NFIL3) (40), interferon regulatory factor-8 (IRF-8) (41), nucleosome remodeling (16) all of
which seem to have incremental but biologically significant effects.
We have utilized CD11b+ LPMCs as representative of colonic macrophages since these cells
are the main sources of IL-12 p40 and IL-10 in the intestinal lamina propria (23, 24). IL-10
and IL-12 p40 production in response to heat-killed enteric bacteria from these cells are
identical in both GF and SPF-raised WT mice. Although this population also includes
CD11b+CD11c+ dendritic cells, CD11b+ CD11c− macrophages are more abundant than
CD11b+CD11c+ dendritic cells in number. Furthermore, we also showed that vast majority
of IL-10 producing cells belongs to CD11b+ CD11c− macrophages, as reported previously
(30).
Histone acetylation and deacetylation are regulated by HATs and HDACs, respectively. We
demonstrated altered histone acetylation on Il12b promoter by IL-10, suggesting that IL-10
represses Il12b transcription by this mechanism. Currently, eighteen HDACs have been
identified in mammalian cells and are classified into 4 classes, of which class I and II are the
major and best characterized groups. Class I HDACs are widely expressed in most cell
types, whereas class II HDACs demonstrate more restricted expression and have roles in cell
differentiation (42). Accordingly, HDAC inhibition has many overarching consequences in
immune cells, including apoptosis (43), differentiation (42, 44), signal transduction (45, 46),
and cytokine production (47–49). Indeed, the class I and II HDAC inhibitor, TSA was
previously described to inhibit LPS-induced pro-inflammatory cytokine expression in
macrophages, including IL-12 p40, when cells were treated with TSA prior to LPS
activation (32). In contrast, treatment with TSA following activation of macrophages leads
to an increased pro-inflammatory response (42, 50). Therefore, to specifically address the
role of HDACs in IL-10 inhibition of Il12b, we treated macrophages with HDAC inhibitors
post-LPS stimulation. Although the magnitude of LPS-induced IL-12 p40 production varied,
both TSA and MS275 significantly diminished IL-12 p40 inhibition by IL-10, indicating that
Kobayashi et al. Page 8













inhibition is HDAC dependent. Among class I and II HDACs, we have shown that HDAC3
is likely to be involved in this process by using the class I specific HDAC inhibitor, MS275.
Moreover, HDAC3-specific knockdown resulted in impaired inhibition of IL-12 p40 by
IL-10, and IL-10-mediated histone deacetylation of Il12b promoter was blocked by MS275.
Furthermore, GF mice colonized with SPF microbiota were used as an in vivo model for
characterizing colonic HDAC induction upon the exposure to commensal bacteria. Hdac3
expression was induced in WT mice but not in Il10−/− mice after colonization. Hdac3
expression inversely correlated with Il12b expression. This finding implicates HDAC3 in
IL-10 mediated Il12b regulation, with colonic Hdac3 induction requiring IL-10 and the
enteric microbiota in vivo. Hence, we provide multiple lines of evidence that HDAC3
contributes to IL-10-mediated Il12b inhibition. However, precise mechanisms for IL-10
control of HDAC3 function on the Il12b promoter await clarification. HDAC3 may function
directly on the Il12b promoter or indirectly through expression of other genes involved in
Il12b regulation. There are multiple factors controlling HDAC activity including its
expression, nuclear translocation and binding to DNA. Additionally, co-repressors such as
SMRT (silencing mediator for retinoid and thyroid receptors), and N-CoR (nuclear receptor
co-repressor) (51) may participate in an HDAC3 regulation. Involvement of STAT3 in this
process is also of interest. STAT3 is both necessary and sufficient for inhibitory effect of
IL-10 on many target pro-inflammatory genes. In fact, Stat3−/− cells and mice show a
phenotype similar to those of Il10−/− (52). Furthermore, Hoentjen et al. demonstrated that
IL-10 regulates p65 recruitment to the Il12b promoter through STAT3 phosphorylation in
bone marrow derived dendritic cells (31). Therefore, it is likely that control of HDAC3
function by IL-10 also involves STAT3.
In conclusion, we provide evidence that IL-10 is a necessary homeostatic factor for
maintaining the anti-inflammatory phenotype of colonic macrophages, without requirement
for in vivo exposure to the enteric microbiota. IL-10 altered the kinetics of histone H4
acetylation on the Il12b promoter. This finding led to the identification of a novel epigenetic
mechanism of IL-10-mediated IL-12 p40 regulation through histone deacetylation by
HDAC3 which is operative in colonic macrophages.
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Figure 1. IL-10 but not the enteric microbiota programs the anti-inflammatory phenotype of
colonic macrophages
WT and Il10−/− colonic CD11b+ LPMCs from GF (left panel) and SPF microbiota colonized
(right panel) mice were stimulated with heat-killed E. coli (EC) or E. faecalis (EF) (MOI =
10) for 24 hours. (A) IL-12/23 p40 and (B) IL-10 secretion was determined by ELISA. (C)
Colonic CD11b+ LPMCs from WT GF mice were stimulated with heat-killed EC or EF
(MOI = 10) ± neutralizing anti-IL-10 (10 μg/ml), IL-10 receptor (anti-IL-10R) antibodies
(10 μg/ml) or isotype control antibodies for 24 hours. IL12/IL-23 p40 secretion was
determined by ELISA. **p < 0.01 relative to isotype stimulated WT CD11b+ LPMCs.
Results represent mean ± SEM from three independent experiments. N.D., not detected. (D)
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Colonic CD11b+ LPMCs from WT, Myd88−/−, and Trif−/− SPF mice were stimulated with
heat-killed EC (MOI = 10). IL-10 secretion was determined by ELISA. Representative result
from 2 independent experiment is shown. N.D., not detected. (E) Colonic lamina propria
mononuclear cells from IL-10 transcriptional reporter, Vert-X mice, are analyzed by flow
cytometry. A representative histogram from 3 independent experiments is shown for GFP,
representing IL-10 expression in gated CD11b+CD11c+ dendritic cells and CD11b+CD11c−
macrophages in SPF-raised Vert-X mice. (F) Germ-free raised (GF) mice were colonized
with the SPF microbiota and cells were isolated 3 and 7 days post-colonization. Results are
shown as mean fluorescence intensity (MFI) for GFP representing IL-10 expression in gated
CD11b+CD11c− macrophages, at each time point of colonization. Results represent mean ±
SEM from three independent experiments.
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Figure 2. IL-10 inhibition of Il12b expression does not involve mRNA stability, NF-κB activation,
MAPK signaling, or nucleosome remodeling
(A) WT and Il10−/− colonic CD11b+ LPMCs were stimulated with heat-killed E. coli (EC)
(MOI=100). Cells were harvested at indicated time points post-EC stimulation and Il12b and
Il10 expression analyzed by real-time RT-PCR. ** p < 0.01 versus WT. (B) WT and Il10−/−
BMDMs were stimulated with LPS (10 ng/ml). Cells were harvested at indicated time points
post-LPS stimulation and Il12b and Il10 expression analyzed by real-time RT-PCR. *p <
0.05; ** p < 0.01 versus LPS stimulated WT BMDMs. (C) WT BMDMs were stimulated
with LPS (10 ng/ml) ± anti-IL-10 or isotype control (iso) antibodies for 2, 4, and 8 hours.
Kinetics of Il12b mRNA expression was analyzed by real-time RT-PCR. ** p < 0.01 versus
LPS stimulated WT BMDMs incubated with isotype control antibody. For real time RT-
PCR experiments, results are expressed as fold induction versus unstimulated control
BMDMs normalized to β-actin (mean ± SEM from three independent experiments). (D) WT
and Il10−/− BMDMs were stimulated with LPS (10 ng/ml) for 2 hours + actinomycin D
(ActD, 5 μg/ml). Cells were harvested at the indicated time points and Il12b expression
analyzed. Results are representative of three independent experiments. (E) Kinetics of NF-
κB and MAPK pathway activation was analyzed by Western immunoblot for indicated
proteins in WT and Il10−/− BMDMs stimulated with LPS (10 ng/ml). Representative results
from three independent experiments are shown. (F) Il10−/− BMDMs were stimulated with
LPS (10 ng/ml) for 3 hours and recombinant IL-10 (20 ng/ml) was added. Cells were
harvested at the indicated time points for mRNA purification and Il12b mRNA expression
was analyzed by real-time PCR. Results are expressed as fold induction versus unstimulated
WT BMDMs normalized to β-actin (mean ± SEM from three independent experiments).
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Figure 3. IL-10 alters histone H4 acetylation kinetics on the Il12b proximal promoter
(A) Effects of IL-10 on nucleosome remodeling at nucleosome 1 (Nuc1) position and (B) an
upstream DNase I hypersensitivity site 1 (HSS1) was monitored by restriction enzyme
accessibility assays. Quantification of SpeI and PstI cleavage products was analyzed by real-
time RT-PCR using primers spanning the Nuc1 and HSS1 regions in the Il12b promoter.
Results are expressed as a percentage of Nuc1 and HSS1 accessibility observed in LPS
stimulated BMDMs relative to unstimulated DNA (mean ± SEM from three independent
experiments). (C) WT and Il10−/− BMDMs were stimulated with LPS (10 ng/ml) for 1.5, 3,
and 6 hours and kinetics of acetylation of histone H4 (AcH4) on the Il12b promoter was
analyzed by ChIP. Results are presented as enrichment (percentage of input DNA) of AcH4
associated with the Il12b promoter. (D) Il10−/− BMDMs were stimulated with LPS (10 ng/
ml) ± recombinant IL-10. Acetylation of histone H4 on the Il12b promoter was analyzed by
ChIP 3 hours following LPS stimulation. Results are presented as enrichment (percentage of
input DNA) of AcH4 associated with the Il12b promoter. (E) WT and Il10−/− BMDMs were
stimulated with LPS (10 ng/ml) for 2 and 6 hours and recruitment of RNA polymerase II
(RNA pol II) to the Il12b promoter was assessed by ChIP. (F) Il10−/− BMDMs were
stimulated with LPS (10 ng/ml) ± recombinant IL-10 for 3 hours and RNA pol II binding on
the Il12b promoter was assessed by ChIP. Results are presented as enrichment (percentage
of input DNA) of RNA pol II promoter occupancy. All ChIP assays are presented as mean ±
SEM of chromatin preparations from three independent experiments. *p < 0.05, **p < 0.01
versus LPS-stimulated BMDMs.
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Figure 4. HDACs are involved in inhibition of Il12b by IL-10
(A) WT BMDMs were stimulated with LPS (10 ng/ml) with or without trichostatin A (TSA)
(100 nM) 1 hour after LPS. Cells were harvested at 3, 6, and 12 hours post-LPS stimulation
and Il12b expression analyzed by real-time RT-PCR. (B, C) Il10−/− BMDMs were
stimulated with LPS (10 ng/ml) and treated with TSA (100 nM) or DMSO 1h post-LPS.
IL-10 (1 ng/ml) was added 2h-post LPS. Il12b expression was determined by real-time RT-
PCR 12 h post-LPS and IL-12 p40 protein by ELISA after 24 hours. Results are presented as
percent Il12b (4C, left) and IL-12 p40 (4C, right) expression by LPS in the presence of
IL-10 relative to LPS alone. (D, E) Il10−/− BMDMs were stimulated with LPS (10 ng/ml)
and treated with MS275, an inhibitor of HDAC1 (IC50=0.3 μM) and HDAC3 (IC50=8
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μM), or DMSO 1 h post-LPS. IL-10 was added 2h-post LPS. Inhibition of Il12b expression
(D) and IL-12 p40 (E) was examined as above. (F) Il10−/− BMDMs transduced HDAC3
shRNA or control scrambled shRNA were analyzed for Hdac3 mRNA expression. Results
are expressed as relative expression (%) versus BMDMs transduced with scrambled shRNA
normalized to β-actin. (G) Il10−/− BMDMs transduced with HDAC3 shRNA or control
scrambled shRNA were stimulated with LPS (10 ng/ml), treated with IL-10 2 hours post-
LPS, and harvested 24 hours post-LPS. Inhibition of IL-12 p40 is presented as above. (H)
Il10−/− BMDMs were stimulated with LPS (10 ng/ml) ± IL-10 in the presence or absence of
MS275 (10 μM). Acetylation of histone H4 on the Il12b promoter was analyzed by ChIP
four hours following LPS stimulation. Results are presented as enrichment (percentage of
input DNA) of AcH4 associated with the Il12b promoter. *p < 0.05 versus LPS + DMSO.
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Figure 5. HDAC3 is a homeostatic factor in IL-10-mediated intestinal immunity
(A)Il10−/− colonic CD11b+ LPMCs were stimulated with heat-killed E. coli (EC, 100 MOI)
and treated with MS275 (1 or 10 μM), TSA (100 nM) or DMSO 1h post-EC. Recombinant
IL-10 (1 ng/ml) was added 2h post-EC. Inhibition of IL-12 p40 was examined as above. All
results represent mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01
versus controls. (B) GF WT and Il10−/− mice were transitioned to an SPF enteric microbiota.
Colonic mucosal Hdac1, Hdac3, and Il12b expression were analyzed before, 3 and 14 days
post-colonization. Results are expressed as fold induction versus WT GF colons normalized
to β-actin (mean ± SEM from four mice per each time point). ***p < 0.005 versus Il10−/−.
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